China includes all approved homegrown anti-COVID drugs in medical insurance
BEIJING, Feb. 8 (Xinhua) -- China has included all homegrown drugs for COVID-19 treatment approved to enter the market in its medical insurance scheme, according to the lastest announcement by the national healthcare authority.
Among these drugs, two tablets were temporarily included in the medical insurance catalog, following a conditional approval by the National Medical Products Administration in late January.
Money spent on these two tablets can be reimbursed by the medical insurance fund before March 31, said the National Healthcare Security Administration (NHSA).
Provincial healthcare authorities were asked to disclose medicine prices, and act in a proper manner under oversight from the public.
Currently, there are more than 600 medications used to treat COVID-19 in China's medical insurance catalog, according to the NHSA.
Photos
Related Stories
- China Speed: back in full gear
- Chinese CDC releases latest COVID-19 figures
- China's COVID response in numbers: "Lives for lives"!
- China's daily ibuprofen, paracetamol production tops 200 mln tablets
- China has necessary conditions for shift in COVID response policies
- China releases details of COVID-19 management shift
- Hospitals scramble to cope with elderly influx
- Changes to COVID management policies explained
- China downgrades COVID management
- China to scrap quarantine requirement for international arrivals
Copyright © 2023 People's Daily Online. All Rights Reserved.